Non-Small-Cell Lung Cancer

News

Pralsetinib Efficacy for Patients With Advanced RET Fusion-Positive NSCLC

06/22/2023

In a phase 1/2 study, pralsetinib demonstrated lasting clinical activity and a well-tolerated safety profile among patients with RET fusion-positive non-small cell lung cancer.

In a phase 1/2 study,...

06/22/2023

Oncology

News

Selpercatinib Superior to Prior Systemic Therapy in RET-Positive NSCLC

06/22/2021

Patients with RET-positive NSCLC who received selpercatinib therapy had a better overall response than those who received prior systemic therapy, according to findings from the phase 1/2 LIBRETTO-001 trial.

Patients with RET-positive NSCLC...

06/22/2021

Oncology

Videos

Dr Baik Discusses Patritumab Deruxtecan for EGFR+ NSCLC

06/16/2021

Christina Baik, MD, MPH, discusses the efficacy and safety of patritumab deruxtecan therapy for patients with EGFR inhibitor-resistant EGFR+ NSCLC.

Christina Baik, MD, MPH,...

06/16/2021

Oncology

News

Sotorasib Safe, Effective for KRAS p.G12C-mutated NSCLC

06/10/2021

Sotorasib therapy demonstrated durable efficacy with manageable safety for previously treated KRAS p.G12C-mutated NSCLC.

Sotorasib therapy demonstrated...

06/10/2021

Oncology

Videos

Dr Spira Talks Amivantamab Plus Lazertinib for Osimertinib-Relapsed, EGFR+ NSCLC

06/09/2021

Alexander Spira, MD, PhD, FACP, discusses the use of amivantamab in combination with lazertinib for the treatment of chemo-naïve patients with osimertinib-relapsed, EGFR+ NSCLC.

Alexander Spira, MD, PhD, FACP,...

06/09/2021

Oncology

Videos

Dr Bruno Highlights Racial Disparities in Testing, Trial Enrollment in NSCLC

06/07/2021

Dr Bruno, MD, discusses the racial disparities in biomarker testing and clinical trial enrollment in patients with NSCLC.

Dr Bruno, MD, discusses the...

06/07/2021

Oncology

Videos

Dr Le Shares Promising Data on Poziotinib for NSCLC With EGFR or HER2 Mutations

04/28/2021

Xiuning Le, MD, PhD, discusses results from the ZENITH20 trial, which showed that twice daily poziotinib improved AEs and retained anti-tumour activity in EGFR+ or HER2+ NSCLC.

Xiuning Le, MD, PhD, discusses...

04/28/2021

Oncology

Conference Insider

Pembrolizumab Plus Chemo Promising for Treatment of NSCLC

03/24/2021

In patients with advanced NSCLC that lack targetable mutations, pembrolizumab combined with chemo has shown promising results, according to research presented at the NCCN annual conference.

In patients with advanced NSCLC...

03/24/2021

Oncology

Conference Insider

Improved Survival With Treatment Guided by Biomarker Testing for NSCLC

03/19/2021

Patients with advanced/metastatic NSCLC have improved survival after treatment guided by biomarker testing, according to research presented at the NCCN Annual Conference.

Patients with...

03/19/2021

Oncology